drugset / Trial / NCT04303130
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
Phase 2
Unknown
52 enrolled
Peking University Cancer Hospital & Institute
Beijing Shijitan Hospital, Capital Medical University · collabChinese PLA General Hospital · collabPeking Union Medical College Hospital · collabPeking University First Hospital · collabPeking University People's Hospital · collabPeking University Third Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, prospective, multi-center clinical trial. designed to evaluate patients with stage IV inability to receive or refuse chemotherapy.Efficacy and safety of first-line treatment with Camrelizumab and Endo in advanced lung squamous cell carcinoma
Timeline
- Start
- 2019-12-31
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |